Oncology - European Medical Journal

This site is intended for healthcare professionals

Continue

Oncology

Filter
EMJ
4 Feb 2016

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…
EMJ
4 Feb 2016

AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
EMJ
4 Feb 2016

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
EMJ
4 Feb 2016

Oncogene-addicted non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
EMJ
4 Feb 2016

Quality of life and new therapeutic options for metastatic castration-resistant prostate cancer

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer…
EMJ
2 Feb 2016

Learn more about the ESMO Asia 2015 Congress

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…
EMJ
1 Feb 2016

Delivering the promise of immunotherapy for melanoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD…
EMJ
25 Jan 2016

Q&A Session – Impact of the GreenLight Laser System for Day-Case Surgery

Mr Gordon Muir answers questions from the audience about the effect and impact of the Greenlight laser system for day-case surgery, which took place on…
We’ve noticed you’re accessing
from North/South America.